Browse the corpus

REFERENCES Alsoufi B, Boshkov LK, Kirby A, et al, "Heparin-Induced Thrombocytopenia (HIT) in Pediatric Cardiac Surgery: An Emerging Cause of Morbidity and Mortality," Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu , 2004, 7:155-71. [PubMed 15283365 ] Arpino PA, Demirjian Z, and Van Cott EM, “Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning From Argatroban to Warfarin,” Pharmacotherapy , 2005, 25(2):157-64. [PubMed 15767231 ] Beiderlinden M, Treschan TA, Gorlinger K, et al, “Argatroban Anticoagulation in Critically Ill Patients,” Ann Pharmacother , 2007, 41(5):749-54. [PubMed 17440009 ] Boshkov LK, Kirby A, Shen I, et al, "Recognition and Management of Heparin-Induced Thrombocytopenia in Pediatric Cardiopulmonary Bypass Patients," Ann Thorac Surg , 2006, 81(6):S2355-9. [PubMed 16731103 ] de Denus S and Spinler SA, “Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca,” Ann Pharmacother , 2003, 37(9):1237-40. [PubMed 12921506 ] GlaxoSmithKline Result Summary, Study No: SKF105043/013, "An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulation Alternatives to Heparin," July 2, 2007. Available at: file://www.gsk-clinicalstudyregister.com/files/pdf/22691.pdf. Hirsh J, Guyatt G, Albers GW, et al, “Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest , 2008, 133(6 Suppl):71-109. [PubMed 18574259 ] Hursting MJ, Dubb J, and Verme-Gibboney CN, "Argatroban Anticoagulation in Pediatric Patients: A Literature Analysis," J Pediatr Hematol Oncol , 2006, 28(1):4-10. [PubMed 16394885 ] Potter KE, Raj A, and Sullivan JE, "Argatroban for Anticoagulation in Pediatric Patients With Heparin-Induced Thrombocytopenia Requiring Extracorporeal Life Support," J Pediatr Hematol Oncol , 2007, 29(4):265-8. [PubMed 17414571 ] Reichert MG, MacGregor DA, Kincaid EH, et al, "Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia," Ann Pharmacother , 2003, 37(5):652-4. [PubMed 12708939 ] Rice L, Hursting MJ, Baillie GM, et al, “Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-Induced Thrombocytopenia,” J Clin Pharmacol , 2007, 47(8):1028-34. [PubMed 17525167 ]

Reichert MG, MacGregor DA, Kincaid EH, et al, "Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia," Ann Pharmacother , 2003, 37(5):652-4. [PubMed 12708939 ] Rice L, Hursting MJ, Baillie GM, et al, “Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-Induced Thrombocytopenia,” J Clin Pharmacol , 2007, 47(8):1028-34. [PubMed 17525167 ] Scott LK, Grier LR, and Conrad SA, "Heparin-Induced Thrombocytopenia in a Pediatric Patient Receiving Extracorporeal Membrane Oxygenation Managed With Argatroban," Pediatr Crit Care Med , 2006, 7(5):473-5. [PubMed 16807510 ] Tcheng WY and Wong W, "Successful Use of Argatroban in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin," Blood , 2004,104:107b-108b. Young G and Boshkov L, "Prospective Study of Direct Thrombin Inhibition With Argatroban in Pediatric Patients Requiring Non-Heparin Anticoagulation," Blood , 2007, 110. Young G, "New Anticoagulants in Children," Hematology Am Soc Hematol Educ Program , 2008, 245-50. [PubMed 19074090 ] Topic 13081 Version 38.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.3 - C21.34 Licensed to: Morehouse School of Medicine | Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]